Description:

SYNTHESIS AND IDENTIFICATION OF NOVEL PRODRUGS OF THE CARDIOTONIC NA/K-ATPASE INHIBITORS FOR THE TREATMENT OF HEART DISEASE, CANCER AND VIRAL INFECTION

INV-13095

INVENTORS: George A. O’Doherty, Hongyan Li, Hua-Ya Leo Wang

 

Description       

Existing cardiac glycosides are associated with a reduced pharmacokinetic potential. Moreover, such glycosides have a limited Na/K ATPase inhibitory activity. There is a serious need to come up with improved structural and functional variants in order to manage unmet therapeutic requirements. This invention discloses a mechanism for synthesis and identification of novel cardiac glycosides (pro-drugs) as selective inhibitors of NA/K ATPase for an effective treatment of related disorders.

Value Proposition

The novel glycosides:

•Are improved variants of already known compounds

•Selectively target specific tissues and disease sites

•Are associated with improved drug therapies as compared to existing counterparts

•Are associated with selectively improved Na/K ATPase inhibitory activities as compared to existing compounds

•Are further associated with improved pharmacokinetic properties such as metabolic stability, solubility, and membrane permeability

•Would be commercially useful for treatment of various disorders such as heart diseases, cancer, and viral infections

 

 

Intellectual Property status

Provisional Application 61/828,277

 

License status

Available for license

 

Patent Information:
For Information, Contact:
Mark Saulich
Associate Director of Commercialization
Northeastern University
m.saulich@northeastern.edu
Inventors:
George O'doherty
Hongyan Li
Hua-Yu Leo Wang
Keywords:
Cancer
Drug Delivery
Pharmaceutical Composition